Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Today's biggest gainers and losers
Visual sector performance
Bumrungrad Hospital operates Thailand's premier private tertiary care hospital in Bangkok, serving as a medical tourism hub with approximately 1.2 million patient visits annually, of which 55-60% are international patients from Middle East, Myanmar, Bangladesh, and other Asian markets. The company commands premium pricing through JCI accreditation, 580+ bed capacity, and specialized centers of excellence in cardiology, oncology, and orthopedics, generating exceptional 30%+ net margins through high-acuity procedures and medical tourism packages.
Bumrungrad operates a high-margin private pay model targeting affluent Thai nationals and international medical tourists willing to pay premium rates for Western-standard care. Revenue per patient averages $800-1,200 versus $200-400 at typical Thai private hospitals. Pricing power derives from brand reputation (40+ years), international accreditations (JCI, ISO), multilingual staff (20+ languages), and specialized clinical capabilities unavailable at competitors. The hospital captures 70-80% gross margins on high-acuity procedures (cardiac surgery, oncology treatments, orthopedic surgeries) while maintaining 4.72x current ratio indicating strong working capital management with minimal receivables risk from cash-pay patients.
International patient volume and mix - Middle Eastern patients (25-30% of international) generate 2-3x revenue per visit versus Asian patients; geopolitical stability in source markets directly impacts quarterly results
Thai baht exchange rate movements - 55-60% revenue from foreign patients creates FX sensitivity; stronger baht reduces affordability for medical tourists and compresses USD-equivalent revenues
Medical tourism policy changes - visa regulations, health insurance portability, and government medical tourism promotion programs in Thailand and source countries
Capacity utilization rates and average revenue per patient - occupancy above 85% signals pricing power; ARPPU growth indicates favorable case mix toward high-acuity procedures
Medical tourism competition intensification - Singapore (Mount Elizabeth, Raffles), Malaysia (Prince Court, Gleneagles), and India (Apollo, Fortis) aggressively targeting same Middle Eastern and Asian patient segments with 30-50% lower pricing; Thailand's cost advantage eroding as domestic wages rise
Thai political instability and safety perceptions - recurring political protests, military coups, and civil unrest damage Thailand's medical tourism brand; 2014 coup caused 15-20% international patient volume decline
Regulatory changes in source markets - governments in Myanmar, Bangladesh increasingly restricting foreign currency outflows for medical treatment abroad; Saudi Arabia and UAE developing domestic tertiary care capacity to reduce medical tourism outflows
Bangkok Hospital network expansion - BDMS operates 50+ hospitals including Bangkok Hospital headquarters competing directly for international patients with similar JCI accreditation and specialist capabilities
Pricing pressure from hospital oversupply - Bangkok private hospital bed capacity grew 25% from 2020-2025 while international tourist arrivals remain 20% below 2019 peak, forcing promotional pricing
Physician retention challenges - specialist doctors increasingly opening private clinics or joining competing hospital networks, fragmenting patient relationships
Capital intensity of maintaining technological edge - medical equipment obsolescence requires $1.3B+ annual capex (5% of revenue) to maintain competitive imaging, surgical robotics, and diagnostic capabilities
Currency mismatch risk - while zero financial debt eliminates leverage risk, 55-60% USD/foreign currency revenues against 80%+ Thai baht costs creates natural FX exposure; 10% baht appreciation reduces operating margins by 200-300bps
moderate - Elective medical procedures and medical tourism exhibit cyclical characteristics as discretionary healthcare spending contracts during recessions. However, the company's focus on high-acuity tertiary care (cardiac, oncology, complex surgeries) provides downside protection as these are less deferrable. International patient volumes correlate with GDP growth in source markets (Middle East oil economies, emerging Southeast Asia). Thai domestic patient volumes (40-45% of total) track local consumer spending and employment conditions among upper-middle class.
Low direct sensitivity given zero debt/equity ratio and $8.7B operating cash flow generation eliminates financing cost exposure. However, rising US rates strengthen USD relative to Thai baht, making medical tourism more expensive for international patients and potentially reducing volumes. Higher rates also compress valuation multiples for high-growth healthcare stocks, impacting P/E rerating potential. Minimal impact on capital allocation as the company self-funds $1.3B annual capex from operating cash flow.
Minimal - cash-pay business model with 90%+ of patients paying upfront or within 30 days eliminates traditional healthcare receivables risk. No exposure to government reimbursement rate changes or insurance company negotiations. Strong 4.72x current ratio and positive working capital indicate no liquidity constraints or need for credit facilities.
growth-at-reasonable-price (GARP) - 26.3% ROE and 30.2% net margins attract quality-focused investors, while 6.0x P/S and 14.3x EV/EBITDA provide reasonable entry versus US hospital operators at 20-25x EBITDA. Recent -24.7% one-year return creates contrarian value opportunity. Medical tourism recovery theme attracts thematic healthcare investors. Zero debt and 194.7% FCF yield appeals to quality/safety-focused allocators concerned about emerging market leverage.
moderate-to-high - stock exhibits 25-35% annual volatility driven by quarterly international patient volume surprises, Thai political events, and baht currency swings. Limited free float and foreign ownership restrictions amplify price movements. Medical tourism exposure creates event risk around geopolitical shocks, pandemics, and travel disruptions not present in domestic-only healthcare stocks.